Targeted MRI provides accurate assessment of new pain in multiple myeloma, enabling focused management and fewer whole-body ...

The impact of glucagon-like peptide-1 agonists on MGUS progression in patients with type 2 diabetes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care. In the opening segment, the moderator ...

Multiple myeloma treatment involved carfilzomib, bendamustine, dexamethasone, and zoledronic acid, alongside MRI scans and radiation therapy. Severe spinal fractures led to significant height loss and ...

Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications. In this episode, experts begin outlining how bispecific ...

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...

Most patients present with asymptomatic, early disease but are found to have abnormal blood and/or urine tests that lead to the diagnosis. In asymptomatic patients, laboratory findings, including ...

The debate around the word “cure.” ...